Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN2 | P17706 | 2/20 | 0.50 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.50 |
| ▸ | PTPN6 | P29350 | 2/20 | 0.50 |
| ▸ | CDC25B | P30305 | 2/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | FNTA | P49354 | 1/20 | 0.45 |
| ▸ | FNTB | P49356 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | LTA4H | P09960 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1711573 | 1.00 | PTPN2 (0.50) | PTPN2PTPN1PTPN6CDC25BGAA | |
| SCHEMBL2190277 | 0.88 | CYP3A4 (0.58) | PTPN2PTPN1PTPN6CDC25BGAA | |
| SCHEMBL2190274 | 0.88 | CYP3A4 (0.58) | PTPN2PTPN1PTPN6CDC25BGAA | |
| SCHEMBL28820831 | 0.88 | CYP3A4 (0.58) | PTPN2PTPN1PTPN6CDC25BGAA | |
| SCHEMBL1710892 | 0.84 | PTPN2 (0.53) | PTPN2PTPN1PTPN6CDC25BGAA | |
| SCHEMBL1710894 | 0.84 | PTPN2 (0.53) | PTPN2PTPN1PTPN6CDC25BGAA | |
| SCHEMBL27608430 | 0.84 | GAA (0.63) | GAAFNTAFNTBCYP3A4CYP2C19 | |
| SCHEMBL27608428 | 0.84 | GAA (0.63) | GAAFNTAFNTBCYP3A4CYP2C19 | |
| SCHEMBL1710952 | 0.82 | PTPN2 (0.55) | PTPN2PTPN1PTPN6CDC25BSMN1; SMN2 | |
| SCHEMBL1710949 | 0.82 | PTPN2 (0.55) | PTPN2PTPN1PTPN6CDC25BSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9150510-B2 | Amino acid derivative | NIPPON ZOKI PHARMACEUTICAL CO., LTD. (JP) | 2015-10-06 | — | — | US | disclosed |
| EP-2345635-A1 | AMINO ACID DERIVATIVE | Nippon Zoki Pharmaceutical Co., Ltd. (JP) | 2011-07-20 | — | — | EP | disclosed |
| US-20110172442-A1 | AMINO ACID DERIVATIVE | NIPPON ZOKI PHARMACEUTICAL CO., LTD. (JP) | 2011-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172442-A1 | AMINO ACID DERIVATIVE | OPRL1, OPRK1, SLC1A1 | PTPN2 3704/4885PTPN1 4062/4885PTPN6 3602/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.